MedDataX Logo

Non-linear Multimodal Microendoscopy for Lung Cancer Pathology

NCT ID: NCT02699229

Last Updated: 2024-12-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2024-01-11

Study Completion Date

2024-12-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

For this study the investigators are looking to do the following:

1. To characterize human lung lesions by nonlinear microscopy using ex vivo tissues.
2. To establish the first spectral/structural database for nonlinear optical microimaging of normal and abnormal lung tissue.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

For this study the investigators are looking to do the following:

1. To characterize human lung lesions by nonlinear microscopy using ex vivo tissues. In particular, to investigate collagen content and ultrastructure with SHG (second harmonic generation) microscopy, to characterize cell and nuclear morphology and lipid vesicle content with THG (third harmonic generation) and CARS (coherent anti-Stokes Raman scattering) microscopy and to conduct spectroscopic and lifetime characterization of MPF (multiphoton fluorescence) signals in cancerous, benign, and normal tissues.
2. To establish the first spectral/structural database for nonlinear optical microimaging of normal and abnormal lung tissue, from which to generate diagnostic algorithms, both to optimize the operating parameters of planned nonlinear endoscopic imaging and to serve as the basis for nonlinear optical histopathology.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Malignant

Tissue sample

No interventions assigned to this group

Benign

Tissue sample

No interventions assigned to this group

Normal

Tissue Sample

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 years or older.
* Patients with confirmed or suspected lung cancer who require lobectomy as part of standard-of-care.

Exclusion Criteria

* Patients deemed on clinical grounds not to be medically fit for a lobectomy
* Patients where there is a high clinical suspicion of lymphoma (to avoid mixing the data sets).
* Patients unable to give informed consent
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Health Network, Toronto

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kazuhiro Yasufuku, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

University Health Network, Toronto

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

14-7485

Identifier Type: -

Identifier Source: org_study_id